매매 가능
LLYNYSE🇺🇸Healthcare · Drug Manufacturers - General
Last updated: 31m ago
52-Week Range
Company Overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalo
🤖 AI Stock Analysis
📊 Valuation: PER 42.92x and Forward PER 23.48x appear undervalued compared to the sector average PER of 85.6x, while PBR 33.22x is high relative to the sector average PBR of -2.43x.
💰 Profitability: ROE is exceptionally high at 101.16%, with strong profitability indicated by a net profit margin of 31.67% and operating margin of 44.9%.
📈 Growth: Demonstrates robust growth with a revenue growth rate of 42.6% and earnings growth rate of 51.4%.
📉 Technical: Currently at 58% of its 52-week range, down 19.1% from its peak, suggesting a correction phase from its highs.
💵 Dividend: Dividend yield of 0.63% and payout ratio of 26.14% indicate limited dividend appeal.
💬 Summary: Presents attractive valuation relative to sector averages, driven by high profitability and growth, but high PBR and low dividend yield warrant consideration. Potential for technical rebound exists due to the correction from its peak.
AI-generated reference material. Not investment advice.Analysis date: 3/15/2026
Valuation
Profitability
Growth & Stability
Dividends
Trading Info
Related News
Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price Cuts
📌 Background: • HSBC has turned bearish on Eli Lilly & Co. shares for the second time in a year. • The firm believes investor expectations for weight-loss drugs are overinflated. 💬 Comment: • Eli Lilly's stock dipped following HSBC's downgrade, highlighting potential overvaluation concerns regarding weight-loss drug market expectations.
[StockHub Alert] Sharp Rise 5, Sharp Drop 5
🚀 Sharp Rise • Lemonade, Inc. ($LMND) $67.56 +17.0% • Bitdeer Technologies Group ($BTDR) $9.23 +12.6% • Ichor Holdings ($ICHR) $47.92 +12.5% • Tandem Diabetes Care, Inc. ($TNDM) $23.78 +8.5% • Six Flags Entertainment Corpora ($FUN) $17.72 +8.1% 💥 Sharp Drop • Damora Therapeutics, Inc. ($DMRA) $22.93 -8.2% • Donnelley Financial Solutions, ($DFIN) $45.64 -7.0% • Semtech Corporation ($SMTC) $82.86 -6.9% • PureCycle Technologies, Inc. ($PCT) $5.42 -6.8% • Eli Lilly and Company ($LLY) $932.02 -5.8%
Eli Lilly shares slide after a bearish Wall Street analyst call — here's our view
📌 Background: • Wall Street analysts have expressed concerns regarding the risk/reward balance in Eli Lilly shares. • Following a bearish analyst call, Eli Lilly's stock experienced a decline. 💬 Comment: • Investors are likely to closely monitor analyst sentiment and re-evaluate their positions in Eli Lilly stock.
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
노보 노디스크 주가, 차세대 비만 치료제 '카그리세마'의 부진으로 16% 넘게 급락. 위고비 출시 이전 수준으로 회귀하며 시총 4,750억 달러 감소. 반면, 일라이 릴리 주가는 4% 상승. 📊 코멘트: 비만 치료제 시장 경쟁 심화 속 옥석 가리기.
노보 노디스크, 체중 감량제 임상 실패로 10% 급락
노보 노디스크의 차세대 체중 감량제 임상 시험이 주요 목표 달성에 실패하며 주가가 최대 10%까지 하락함. 📊 코멘트: 체중 감량제 시장 경쟁 심화 전망.